Know Cancer

forgot password

An Open Label, Multi-Center, Phase II Study to Investigate the Safety and Efficacy of SDX-101 (R-Etodolac) in Patients With Relapsed or Refractory Multiple Myeloma (MM)

Phase 2
18 Years
Not Enrolling
Multiple Myeloma

Thank you

Trial Information

An Open Label, Multi-Center, Phase II Study to Investigate the Safety and Efficacy of SDX-101 (R-Etodolac) in Patients With Relapsed or Refractory Multiple Myeloma (MM)

Inclusion Criteria:

1. Previously diagnosis of multiple myeloma as determined by any two of the major
criteria, or major criteria 1 plus minor criteria b, c, or d, or major criteria 3
plus minor criteria a or c, or minor criteria a, b and c or a, b, and d.

Major criteria:

- Plasmacytomas on tissue biopsy

- Bone marrow plasmacytomas (>30% plasma cells)

- Monoclonal immunoglobulin spike on serum electrophoresis immunoglobulin G (IgG)
>3.5 g/dl or immunoglobulin A (IGA) > 2.0 g/dl; kappa or lambda light chain
excretion > 1 g/day on 24 hour urine protein electrophoresis

Minor criteria:

1. Bone marrow plasmacytomas (10 to 30% plasma cells)

2. Monoclonal immunoglobulin present but of lesser magnitude than given under major

3. Lytic bone lesions

4. Normal IgM < 50 mg/dl, IgA < 100 mg/dl, or IgG < 600 mg/dl

2. Has relapsed or refractory disease as determined by the following:

Relapsed disease:

• Disease progression developed following the achievement of at least stable disease
or better to an anti-myeloma regimen.

Refractory disease:

• Disease progression developed during therapy with an anti-myeloma regimen prior to
the achievement of at least stable disease or better. Includes the development of
disease progression during maintenance or consolidation therapy with glucocorticoids
or cytotoxic chemotherapy.

3. Age > 18 at signing of informed consent.

4. ECOG performance status  0-2.

5. Renal function  1.5 x upper limit normal (blood urea nitrogen [BUN], serum

6. Liver function ≤ 1.5 times upper limit of normal (total bilirubin, SGOT (AST) and
SGPT (ALT) values).

7. Female patients of childbearing potential must have a negative pregnancy test (serum
-human chorionic gonadotropin, -HCG); men and women of reproductive potential must
employ effective contraceptive methods while on study therapy, and for 1 month
following completion of treatment.

8. Signed IRB-approved informed consent by patient prior to all study related

Exclusion Criteria:

1. History of a prior malignancy with in the last 3 years with the exception of resected
basal cell carcinoma, in situ cervical cancer at any time or other resected
malignancies with no evidence of recurrence 5 or more years since diagnosis.

2. Patients with a hemoglobin count of < 8.0 g/dl, platelet count of < 50,000 cells/mm3,
or an absolute neutrophil count (ANC) of < 1000 cells/mm3.

3. Serious infection, medical condition, or psychiatric condition that, in the opinion
of the investigator, places the subject at unacceptable risk or might interfere with
the achievement of the study objectives.

4. Chronic viral infection: positive hepatitis B or hepatitis C serology, known positive
for human immunodeficiency virus (HIV) or human T-leukemia/lymphoma virus (HTLV).

5. Peptic ulcer disease (PUD) requiring treatment or surgical intervention within the
last 2 years.

6. The use of steroids or chronic nonsteriodal anti-inflammatory drugs 28 days prior to
the initiation of study medication.

7. Treatment with chemotherapy for the treatment of multiple myeloma or any
investigational agent within 6 weeks of study entry.

8. History of allergy to NSAIDs or aspirin-induced asthma.

9. Pregnancy or currently breast feeding.

Type of Study:


Study Design:

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment


United States: Food and Drug Administration

Study ID:




Start Date:

Completion Date:

Related Keywords:

  • Multiple Myeloma
  • Multiple Myeloma
  • Relapsed Multiple Myeloma
  • Refractory Multiple Myeloma
  • Multiple Myeloma
  • Neoplasms, Plasma Cell



MD Anderson Cancer Center Houston, Texas  77030-4096
Johns Hopkins School of Medicine Baltimore, Maryland  21205
Cleveland Clinic Foundation Cleveland, Ohio  44195
Roswell Park Cancer Institute Buffalo, New York  14263
University of Pittsburgh Cancer Institute Pittsburgh, Pennsylvania  15213
Emory University School of Medicine Atlanta, Georgia  30322
H. Lee Moffitt Cancer Center Tampa, Florida  33612
University of North Carolina at Chapel Hill Chapel Hill, North Carolina  27599